Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 120 | 2024 | 11097 | 5.780 |
Why?
|
Androgen Antagonists | 55 | 2024 | 1412 | 5.590 |
Why?
|
Phenylthiohydantoin | 26 | 2022 | 206 | 5.020 |
Why?
|
Androstenes | 21 | 2021 | 177 | 4.020 |
Why?
|
Receptors, Androgen | 37 | 2022 | 1089 | 3.910 |
Why?
|
Prostate-Specific Antigen | 63 | 2024 | 2463 | 3.900 |
Why?
|
Antineoplastic Agents, Hormonal | 35 | 2023 | 1536 | 3.430 |
Why?
|
Nitriles | 34 | 2024 | 980 | 2.760 |
Why?
|
Androstadienes | 10 | 2019 | 348 | 2.690 |
Why?
|
Taxoids | 26 | 2022 | 665 | 2.650 |
Why?
|
Neoadjuvant Therapy | 21 | 2024 | 2902 | 2.230 |
Why?
|
Prostatectomy | 26 | 2024 | 1786 | 2.130 |
Why?
|
Benzamides | 26 | 2022 | 1376 | 2.100 |
Why?
|
Leuprolide | 11 | 2024 | 313 | 2.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 49 | 2024 | 11872 | 1.820 |
Why?
|
Prednisone | 21 | 2024 | 1566 | 1.760 |
Why?
|
Androgens | 25 | 2024 | 1281 | 1.710 |
Why?
|
Antineoplastic Agents | 33 | 2022 | 13650 | 1.650 |
Why?
|
Benzimidazoles | 5 | 2019 | 862 | 1.570 |
Why?
|
Kallikreins | 8 | 2020 | 219 | 1.530 |
Why?
|
Neoplasm Metastasis | 38 | 2024 | 4892 | 1.470 |
Why?
|
Radium | 3 | 2024 | 70 | 1.410 |
Why?
|
Steroid 17-alpha-Hydroxylase | 7 | 2014 | 99 | 1.340 |
Why?
|
Neoplasms, Hormone-Dependent | 12 | 2014 | 409 | 1.310 |
Why?
|
Neoplasm Recurrence, Local | 25 | 2024 | 9410 | 1.270 |
Why?
|
Adenocarcinoma | 19 | 2024 | 6360 | 1.260 |
Why?
|
Drug Resistance, Neoplasm | 26 | 2024 | 5332 | 1.210 |
Why?
|
Germ-Line Mutation | 10 | 2022 | 1885 | 0.990 |
Why?
|
Bone Neoplasms | 13 | 2024 | 2563 | 0.890 |
Why?
|
Male | 201 | 2024 | 364203 | 0.850 |
Why?
|
Thiohydantoins | 2 | 2021 | 19 | 0.850 |
Why?
|
Genetic Counseling | 3 | 2023 | 635 | 0.830 |
Why?
|
Tosyl Compounds | 6 | 2018 | 115 | 0.740 |
Why?
|
Prostate | 14 | 2024 | 1761 | 0.720 |
Why?
|
Androgen Receptor Antagonists | 8 | 2022 | 123 | 0.720 |
Why?
|
Estramustine | 8 | 2013 | 35 | 0.670 |
Why?
|
Anilides | 7 | 2018 | 413 | 0.660 |
Why?
|
Treatment Outcome | 53 | 2024 | 65295 | 0.600 |
Why?
|
Aged | 100 | 2024 | 171319 | 0.600 |
Why?
|
Urogenital Neoplasms | 1 | 2019 | 130 | 0.590 |
Why?
|
Ketoconazole | 5 | 2014 | 95 | 0.580 |
Why?
|
Neoplastic Cells, Circulating | 5 | 2021 | 949 | 0.570 |
Why?
|
Androstenols | 3 | 2013 | 25 | 0.570 |
Why?
|
Azasteroids | 4 | 2014 | 37 | 0.560 |
Why?
|
Humans | 207 | 2024 | 767040 | 0.560 |
Why?
|
Middle Aged | 100 | 2024 | 223233 | 0.560 |
Why?
|
BRCA2 Protein | 5 | 2023 | 802 | 0.520 |
Why?
|
Organic Anion Transporters | 4 | 2019 | 101 | 0.510 |
Why?
|
DNA Repair | 3 | 2021 | 2050 | 0.470 |
Why?
|
Disease-Free Survival | 20 | 2022 | 6844 | 0.470 |
Why?
|
Neoplasm Staging | 22 | 2024 | 11217 | 0.450 |
Why?
|
Video Recording | 1 | 2019 | 977 | 0.440 |
Why?
|
Goserelin | 2 | 2013 | 126 | 0.430 |
Why?
|
Testosterone | 13 | 2024 | 2490 | 0.390 |
Why?
|
Disease Progression | 27 | 2020 | 13646 | 0.390 |
Why?
|
DNA Damage | 1 | 2021 | 2469 | 0.370 |
Why?
|
Urologic Neoplasms | 4 | 2016 | 312 | 0.360 |
Why?
|
Progesterone | 2 | 2014 | 752 | 0.350 |
Why?
|
Castration | 5 | 2024 | 149 | 0.340 |
Why?
|
Genetic Testing | 6 | 2024 | 3591 | 0.340 |
Why?
|
Orchiectomy | 13 | 2015 | 466 | 0.330 |
Why?
|
Germ Cells | 3 | 2022 | 644 | 0.320 |
Why?
|
Aged, 80 and over | 41 | 2024 | 59548 | 0.310 |
Why?
|
5-alpha Reductase Inhibitors | 3 | 2020 | 112 | 0.300 |
Why?
|
Hormone Antagonists | 1 | 2008 | 108 | 0.300 |
Why?
|
Urinary Bladder Neoplasms | 6 | 2020 | 2186 | 0.290 |
Why?
|
Combined Modality Therapy | 9 | 2021 | 8535 | 0.290 |
Why?
|
BRCA1 Protein | 3 | 2023 | 1155 | 0.290 |
Why?
|
Biopsy | 7 | 2021 | 6777 | 0.280 |
Why?
|
Mifepristone | 1 | 2008 | 151 | 0.280 |
Why?
|
Carcinoma | 5 | 2023 | 2326 | 0.280 |
Why?
|
Radiography, Interventional | 1 | 2014 | 1129 | 0.270 |
Why?
|
Molecular Targeted Therapy | 4 | 2019 | 2824 | 0.270 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 3511 | 0.260 |
Why?
|
Survival Analysis | 17 | 2018 | 10092 | 0.260 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2020 | 3552 | 0.260 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2023 | 277 | 0.260 |
Why?
|
Drug Administration Schedule | 9 | 2018 | 4855 | 0.260 |
Why?
|
Cancer Vaccines | 1 | 2013 | 1041 | 0.250 |
Why?
|
Medical Oncology | 2 | 2018 | 2341 | 0.250 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2014 | 2028 | 0.250 |
Why?
|
Chromogranins | 1 | 2005 | 160 | 0.240 |
Why?
|
Mutation | 13 | 2024 | 30211 | 0.240 |
Why?
|
Phthalazines | 2 | 2024 | 397 | 0.230 |
Why?
|
Rho(D) Immune Globulin | 1 | 2003 | 34 | 0.220 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2023 | 48 | 0.220 |
Why?
|
Follow-Up Studies | 17 | 2020 | 39317 | 0.220 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2022 | 878 | 0.220 |
Why?
|
Carcinoma, Transitional Cell | 3 | 2015 | 790 | 0.210 |
Why?
|
Prospective Studies | 14 | 2024 | 54886 | 0.210 |
Why?
|
Urology | 2 | 2018 | 384 | 0.210 |
Why?
|
Neoplasm, Residual | 2 | 2019 | 1012 | 0.200 |
Why?
|
Prognosis | 18 | 2024 | 29963 | 0.200 |
Why?
|
Genetic Predisposition to Disease | 5 | 2022 | 18063 | 0.200 |
Why?
|
Hydrocortisone | 3 | 2009 | 1840 | 0.200 |
Why?
|
3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2020 | 74 | 0.200 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2023 | 1788 | 0.200 |
Why?
|
Retrospective Studies | 23 | 2024 | 81659 | 0.190 |
Why?
|
Sequence Analysis | 1 | 2022 | 240 | 0.190 |
Why?
|
Salvage Therapy | 2 | 2023 | 1271 | 0.180 |
Why?
|
Gonadotropin-Releasing Hormone | 4 | 2017 | 1149 | 0.180 |
Why?
|
Enzyme Inhibitors | 1 | 2011 | 3726 | 0.180 |
Why?
|
Dehydroepiandrosterone Sulfate | 3 | 2019 | 241 | 0.170 |
Why?
|
Risk Assessment | 10 | 2021 | 24299 | 0.170 |
Why?
|
Sesquiterpenes | 1 | 2020 | 175 | 0.170 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2020 | 3608 | 0.170 |
Why?
|
Neuregulin-1 | 1 | 2020 | 136 | 0.170 |
Why?
|
Radioisotopes | 2 | 2023 | 509 | 0.170 |
Why?
|
Insulin Resistance | 2 | 2024 | 3986 | 0.160 |
Why?
|
Research Subjects | 1 | 2021 | 249 | 0.160 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2003 | 245 | 0.160 |
Why?
|
Paclitaxel | 3 | 2001 | 1728 | 0.160 |
Why?
|
Urothelium | 2 | 2011 | 275 | 0.160 |
Why?
|
Neoplasm Proteins | 3 | 2018 | 3599 | 0.160 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2003 | 667 | 0.160 |
Why?
|
DNA, Neoplasm | 3 | 2017 | 1741 | 0.160 |
Why?
|
Preoperative Period | 1 | 2021 | 564 | 0.150 |
Why?
|
Bone Marrow Neoplasms | 1 | 1999 | 101 | 0.150 |
Why?
|
Tumor Burden | 1 | 2024 | 1903 | 0.150 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2018 | 93 | 0.150 |
Why?
|
Double-Blind Method | 9 | 2021 | 12451 | 0.150 |
Why?
|
Multicenter Studies as Topic | 3 | 2024 | 1733 | 0.150 |
Why?
|
Signal Transduction | 10 | 2022 | 23621 | 0.150 |
Why?
|
DNA Mismatch Repair | 2 | 2018 | 431 | 0.150 |
Why?
|
Time Factors | 14 | 2021 | 40154 | 0.150 |
Why?
|
Drug Therapy, Combination | 3 | 2021 | 6310 | 0.150 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8048 | 0.150 |
Why?
|
Vitis | 1 | 2017 | 19 | 0.150 |
Why?
|
Gene Dosage | 3 | 2020 | 1211 | 0.150 |
Why?
|
Point Mutation | 3 | 2004 | 1591 | 0.150 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2022 | 343 | 0.150 |
Why?
|
Genes, BRCA2 | 1 | 2021 | 591 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 10 | 2020 | 6513 | 0.140 |
Why?
|
Maximum Tolerated Dose | 3 | 2015 | 896 | 0.140 |
Why?
|
Repressor Proteins | 3 | 2024 | 2979 | 0.140 |
Why?
|
Retreatment | 2 | 2015 | 598 | 0.140 |
Why?
|
Survival Rate | 11 | 2020 | 12823 | 0.140 |
Why?
|
Gene Expression Profiling | 5 | 2021 | 9532 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2022 | 8628 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2020 | 563 | 0.130 |
Why?
|
United States | 16 | 2024 | 72971 | 0.130 |
Why?
|
Tissue Extracts | 1 | 2016 | 139 | 0.130 |
Why?
|
DNA Nucleotidylexotransferase | 1 | 1996 | 64 | 0.130 |
Why?
|
Pain Perception | 1 | 2017 | 198 | 0.130 |
Why?
|
Cancer Care Facilities | 1 | 2019 | 427 | 0.130 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2015 | 2061 | 0.120 |
Why?
|
Societies, Medical | 2 | 2018 | 3964 | 0.120 |
Why?
|
Hormones | 3 | 2023 | 865 | 0.120 |
Why?
|
Neuroendocrine Tumors | 1 | 2022 | 659 | 0.120 |
Why?
|
Membrane Proteins | 2 | 2024 | 7868 | 0.120 |
Why?
|
Immunotherapy | 3 | 2018 | 4745 | 0.120 |
Why?
|
3-Hydroxysteroid Dehydrogenases | 1 | 2014 | 34 | 0.120 |
Why?
|
Paternal Exposure | 1 | 2015 | 100 | 0.120 |
Why?
|
Hydroxyprostaglandin Dehydrogenases | 1 | 2014 | 31 | 0.120 |
Why?
|
Cell Line, Tumor | 8 | 2022 | 17097 | 0.120 |
Why?
|
Biological Transport | 2 | 2017 | 2084 | 0.120 |
Why?
|
Receptors, Glucocorticoid | 1 | 2017 | 309 | 0.120 |
Why?
|
Organoplatinum Compounds | 1 | 2016 | 406 | 0.120 |
Why?
|
Microsatellite Instability | 1 | 2018 | 726 | 0.120 |
Why?
|
Erythropoiesis | 1 | 2018 | 691 | 0.120 |
Why?
|
Protein Isoforms | 1 | 2019 | 1716 | 0.120 |
Why?
|
Serine | 1 | 2018 | 828 | 0.120 |
Why?
|
Consensus | 5 | 2024 | 3207 | 0.120 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2014 | 134 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2024 | 10393 | 0.110 |
Why?
|
Anoikis | 1 | 2014 | 49 | 0.110 |
Why?
|
Erythropoietin | 1 | 2018 | 718 | 0.110 |
Why?
|
Plant Extracts | 1 | 2017 | 496 | 0.110 |
Why?
|
Piperazines | 1 | 2024 | 2548 | 0.110 |
Why?
|
Multivariate Analysis | 9 | 2022 | 12069 | 0.110 |
Why?
|
Radiography | 5 | 2016 | 6975 | 0.110 |
Why?
|
Drug Therapy | 1 | 2016 | 504 | 0.110 |
Why?
|
Nuclear Proteins | 3 | 2024 | 5794 | 0.110 |
Why?
|
Patient Preference | 2 | 2018 | 947 | 0.110 |
Why?
|
Radionuclide Imaging | 2 | 2014 | 1987 | 0.110 |
Why?
|
Lutetium | 2 | 2023 | 38 | 0.110 |
Why?
|
Mice, SCID | 4 | 2020 | 2626 | 0.110 |
Why?
|
Protective Agents | 1 | 2014 | 150 | 0.110 |
Why?
|
Heterocyclic Compounds, 1-Ring | 2 | 2023 | 68 | 0.100 |
Why?
|
PTEN Phosphohydrolase | 2 | 2018 | 1119 | 0.100 |
Why?
|
Drugs, Investigational | 1 | 2014 | 211 | 0.100 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 1105 | 0.100 |
Why?
|
Imidazolidines | 2 | 2005 | 38 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 2 | 2022 | 1883 | 0.100 |
Why?
|
Oncogenes | 1 | 2018 | 1232 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2018 | 2883 | 0.100 |
Why?
|
Pyrimidines | 2 | 2015 | 3044 | 0.100 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 267 | 0.100 |
Why?
|
Sequence Analysis, DNA | 2 | 2021 | 4780 | 0.100 |
Why?
|
Fluorine Radioisotopes | 1 | 2015 | 405 | 0.100 |
Why?
|
Decision Making | 2 | 2017 | 3951 | 0.100 |
Why?
|
Muscles | 2 | 2020 | 1576 | 0.100 |
Why?
|
Organic Anion Transporters, Sodium-Independent | 1 | 2011 | 28 | 0.090 |
Why?
|
Adult | 24 | 2021 | 223317 | 0.090 |
Why?
|
Practice Guidelines as Topic | 6 | 2024 | 7435 | 0.090 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2014 | 631 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2003 | 1946 | 0.090 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 892 | 0.090 |
Why?
|
Down-Regulation | 1 | 2018 | 2931 | 0.090 |
Why?
|
Dipeptides | 2 | 2023 | 386 | 0.090 |
Why?
|
Quality of Life | 6 | 2017 | 13485 | 0.090 |
Why?
|
Positron-Emission Tomography | 3 | 2022 | 6550 | 0.090 |
Why?
|
Glucocorticoids | 2 | 2018 | 2163 | 0.090 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 3944 | 0.090 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 2 | 2020 | 105 | 0.090 |
Why?
|
Delphi Technique | 2 | 2024 | 891 | 0.090 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2024 | 638 | 0.090 |
Why?
|
Cholestenone 5 alpha-Reductase | 1 | 2009 | 21 | 0.090 |
Why?
|
Ureteral Neoplasms | 1 | 2011 | 106 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2666 | 0.080 |
Why?
|
Cystectomy | 1 | 2014 | 603 | 0.080 |
Why?
|
Chromogranin A | 2 | 2008 | 47 | 0.080 |
Why?
|
Chromatography, Liquid | 1 | 2013 | 996 | 0.080 |
Why?
|
Testicular Neoplasms | 1 | 2015 | 806 | 0.080 |
Why?
|
Macrophages | 1 | 2024 | 5785 | 0.080 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7611 | 0.080 |
Why?
|
DNA Helicases | 1 | 2014 | 854 | 0.080 |
Why?
|
Pilot Projects | 3 | 2019 | 8732 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3414 | 0.080 |
Why?
|
Drug Approval | 1 | 2016 | 820 | 0.080 |
Why?
|
Bone Marrow | 3 | 2005 | 2926 | 0.080 |
Why?
|
Immunohistochemistry | 6 | 2018 | 11063 | 0.080 |
Why?
|
Genomics | 3 | 2022 | 5924 | 0.080 |
Why?
|
Nanotechnology | 1 | 2014 | 702 | 0.080 |
Why?
|
Carboplatin | 2 | 2008 | 790 | 0.070 |
Why?
|
DNA Mutational Analysis | 4 | 2017 | 4114 | 0.070 |
Why?
|
Radiopharmaceuticals | 2 | 2014 | 2702 | 0.070 |
Why?
|
Thiazoles | 1 | 2015 | 1530 | 0.070 |
Why?
|
Cisplatin | 3 | 2020 | 1656 | 0.070 |
Why?
|
Lymph Nodes | 2 | 2015 | 3468 | 0.070 |
Why?
|
Internet | 1 | 2019 | 3114 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4903 | 0.070 |
Why?
|
Hyperaldosteronism | 1 | 2010 | 252 | 0.070 |
Why?
|
Surgery, Computer-Assisted | 1 | 2014 | 996 | 0.070 |
Why?
|
Kidney Neoplasms | 2 | 2015 | 4282 | 0.070 |
Why?
|
Neoplasm Invasiveness | 2 | 2014 | 3611 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2015 | 2457 | 0.070 |
Why?
|
Angiogenesis Inhibitors | 2 | 2013 | 2055 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 6 | 2019 | 36582 | 0.060 |
Why?
|
Mass Spectrometry | 1 | 2013 | 2201 | 0.060 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 15424 | 0.060 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1615 | 0.060 |
Why?
|
Models, Molecular | 1 | 2015 | 5388 | 0.060 |
Why?
|
Sirolimus | 1 | 2012 | 1539 | 0.060 |
Why?
|
Primary Health Care | 1 | 2022 | 4746 | 0.060 |
Why?
|
Epigenesis, Genetic | 4 | 2020 | 3828 | 0.060 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2011 | 2428 | 0.060 |
Why?
|
Receptor, erbB-2 | 1 | 2016 | 2599 | 0.060 |
Why?
|
Intestinal Mucosa | 1 | 1996 | 3043 | 0.060 |
Why?
|
Alternative Splicing | 2 | 2021 | 1103 | 0.060 |
Why?
|
Pattern Recognition, Automated | 1 | 2011 | 987 | 0.060 |
Why?
|
Radiotherapy | 1 | 2011 | 1500 | 0.060 |
Why?
|
Flutamide | 3 | 1999 | 95 | 0.060 |
Why?
|
Hemoglobinuria | 1 | 2003 | 12 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 1982 | 0.060 |
Why?
|
Osteoporosis | 1 | 2013 | 1604 | 0.060 |
Why?
|
Patient Selection | 3 | 2023 | 4256 | 0.050 |
Why?
|
Rh-Hr Blood-Group System | 1 | 2003 | 64 | 0.050 |
Why?
|
Testis | 2 | 2017 | 783 | 0.050 |
Why?
|
Risk | 3 | 2021 | 9606 | 0.050 |
Why?
|
Body Composition | 2 | 2024 | 2454 | 0.050 |
Why?
|
SEER Program | 2 | 2018 | 1444 | 0.050 |
Why?
|
Receptors, Estrogen | 2 | 2001 | 2252 | 0.050 |
Why?
|
Neoplasms | 2 | 2022 | 22350 | 0.050 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 505 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 3249 | 0.050 |
Why?
|
Africa | 1 | 2024 | 725 | 0.050 |
Why?
|
Cohort Studies | 6 | 2023 | 41718 | 0.050 |
Why?
|
Animals | 12 | 2024 | 168965 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2022 | 3667 | 0.050 |
Why?
|
Molecular Sequence Data | 3 | 2003 | 17608 | 0.050 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2023 | 332 | 0.050 |
Why?
|
Palliative Care | 3 | 2006 | 3641 | 0.050 |
Why?
|
Mice | 8 | 2024 | 81912 | 0.050 |
Why?
|
Cell Line | 4 | 2022 | 15567 | 0.050 |
Why?
|
Credentialing | 1 | 2022 | 114 | 0.050 |
Why?
|
Mitoxantrone | 3 | 2006 | 148 | 0.050 |
Why?
|
Risk Factors | 10 | 2020 | 74886 | 0.050 |
Why?
|
Prostatic Diseases | 1 | 2001 | 55 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2022 | 300 | 0.050 |
Why?
|
Adrenal Cortex | 1 | 2021 | 134 | 0.050 |
Why?
|
Cell Communication | 1 | 2008 | 1660 | 0.050 |
Why?
|
Remission Induction | 1 | 2006 | 2408 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2003 | 6067 | 0.040 |
Why?
|
Gynecomastia | 1 | 2021 | 88 | 0.040 |
Why?
|
DNA-Binding Proteins | 2 | 2014 | 9612 | 0.040 |
Why?
|
Estrogens | 1 | 2007 | 1536 | 0.040 |
Why?
|
MicroRNAs | 1 | 2016 | 3792 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2015 | 3186 | 0.040 |
Why?
|
Cyclin E | 1 | 2020 | 155 | 0.040 |
Why?
|
Research Design | 1 | 2016 | 6210 | 0.040 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2021 | 301 | 0.040 |
Why?
|
Female | 15 | 2023 | 396660 | 0.040 |
Why?
|
Body Fat Distribution | 1 | 2021 | 246 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2024 | 713 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4648 | 0.040 |
Why?
|
Blood Proteins | 1 | 2004 | 1190 | 0.040 |
Why?
|
Steroid 16-alpha-Hydroxylase | 1 | 2018 | 12 | 0.040 |
Why?
|
Base Sequence | 2 | 2003 | 12414 | 0.040 |
Why?
|
Erythrocyte Transfusion | 1 | 2003 | 575 | 0.040 |
Why?
|
Bone and Bones | 3 | 2015 | 2587 | 0.040 |
Why?
|
Erythrocyte Count | 1 | 2018 | 157 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12536 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 1996 | 10254 | 0.040 |
Why?
|
Mice, Inbred ICR | 1 | 2018 | 361 | 0.040 |
Why?
|
Cell Count | 1 | 2022 | 1825 | 0.040 |
Why?
|
Probability | 1 | 2003 | 2476 | 0.040 |
Why?
|
Glucuronides | 1 | 2017 | 20 | 0.040 |
Why?
|
Spliceosomes | 1 | 2018 | 116 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2003 | 2920 | 0.040 |
Why?
|
Depression | 1 | 2017 | 8234 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2008 | 4247 | 0.040 |
Why?
|
Codon | 1 | 1999 | 599 | 0.040 |
Why?
|
Dihydrotestosterone | 2 | 2013 | 195 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 705 | 0.030 |
Why?
|
Administration, Oral | 2 | 2016 | 4026 | 0.030 |
Why?
|
Cullin Proteins | 1 | 2018 | 180 | 0.030 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2018 | 246 | 0.030 |
Why?
|
Gene Duplication | 1 | 2018 | 315 | 0.030 |
Why?
|
Genes, myc | 1 | 2018 | 391 | 0.030 |
Why?
|
Testosterone Congeners | 1 | 2017 | 62 | 0.030 |
Why?
|
Genotype | 3 | 2017 | 13035 | 0.030 |
Why?
|
Lymphatic Metastasis | 2 | 2015 | 2900 | 0.030 |
Why?
|
Lipid Peroxidation | 1 | 2017 | 276 | 0.030 |
Why?
|
DNA Methylation | 2 | 2022 | 4426 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2020 | 715 | 0.030 |
Why?
|
Sulfates | 1 | 2017 | 379 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2017 | 16036 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 754 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2012 | 2850 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2017 | 297 | 0.030 |
Why?
|
Liver | 2 | 2024 | 7578 | 0.030 |
Why?
|
Diagnostic Imaging | 2 | 2023 | 3530 | 0.030 |
Why?
|
Ferritins | 1 | 2018 | 601 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2001 | 4572 | 0.030 |
Why?
|
Alkaline Phosphatase | 1 | 2018 | 861 | 0.030 |
Why?
|
Phenotype | 3 | 2018 | 16718 | 0.030 |
Why?
|
Drug Combinations | 1 | 2021 | 2086 | 0.030 |
Why?
|
Superoxide Dismutase | 1 | 2017 | 596 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20741 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2018 | 661 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2018 | 2012 | 0.030 |
Why?
|
Adrenal Glands | 1 | 2017 | 557 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 3 | 2018 | 5693 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2022 | 2217 | 0.030 |
Why?
|
Androsterone | 1 | 2013 | 14 | 0.030 |
Why?
|
Filgrastim | 1 | 2014 | 131 | 0.030 |
Why?
|
Proteome | 1 | 2004 | 1890 | 0.030 |
Why?
|
Renal Dialysis | 1 | 2003 | 1790 | 0.030 |
Why?
|
Platinum | 1 | 2015 | 219 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2019 | 838 | 0.030 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 777 | 0.030 |
Why?
|
Pain Threshold | 1 | 2017 | 607 | 0.030 |
Why?
|
Bone Marrow Diseases | 1 | 1995 | 234 | 0.030 |
Why?
|
Drug Synergism | 1 | 2017 | 1759 | 0.030 |
Why?
|
Lipids | 1 | 2024 | 3322 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2018 | 1141 | 0.030 |
Why?
|
Vinblastine | 1 | 2014 | 482 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2024 | 3700 | 0.030 |
Why?
|
Hemoglobins | 1 | 2018 | 1531 | 0.030 |
Why?
|
Indazoles | 1 | 2014 | 306 | 0.020 |
Why?
|
History, 20th Century | 1 | 2020 | 2765 | 0.020 |
Why?
|
Registries | 2 | 2019 | 8351 | 0.020 |
Why?
|
Haplotypes | 1 | 2018 | 2722 | 0.020 |
Why?
|
DNA, Complementary | 1 | 1995 | 1989 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 1697 | 0.020 |
Why?
|
Spermatozoa | 1 | 2015 | 625 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 1996 | 2472 | 0.020 |
Why?
|
DNA Primers | 1 | 1996 | 2827 | 0.020 |
Why?
|
Estradiol | 2 | 1997 | 1951 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1366 | 0.020 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2014 | 415 | 0.020 |
Why?
|
Platinum Compounds | 1 | 2011 | 94 | 0.020 |
Why?
|
Endonucleases | 1 | 2014 | 371 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1639 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 615 | 0.020 |
Why?
|
Pelvis | 1 | 2015 | 736 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 14672 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2022 | 12793 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2016 | 2221 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 1996 | 1560 | 0.020 |
Why?
|
Canada | 1 | 2015 | 2127 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2952 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2017 | 1997 | 0.020 |
Why?
|
Hypertension | 2 | 2021 | 8615 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2017 | 1814 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2018 | 3427 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4968 | 0.020 |
Why?
|
Proteins | 1 | 2023 | 6001 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2629 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2018 | 2429 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2020 | 5796 | 0.020 |
Why?
|
Protozoan Infections | 1 | 1988 | 38 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 1188 | 0.020 |
Why?
|
Cytokines | 1 | 2003 | 7446 | 0.020 |
Why?
|
Pain | 2 | 2018 | 5101 | 0.020 |
Why?
|
Intestinal Diseases, Parasitic | 1 | 1988 | 64 | 0.020 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2008 | 128 | 0.020 |
Why?
|
Cell Cycle | 1 | 1996 | 2927 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 1995 | 6106 | 0.020 |
Why?
|
Methotrexate | 1 | 2014 | 1718 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2229 | 0.020 |
Why?
|
Phosphorylation | 1 | 2018 | 8310 | 0.020 |
Why?
|
Disease Management | 1 | 2018 | 2531 | 0.020 |
Why?
|
Cause of Death | 1 | 2018 | 3717 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2018 | 1882 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2016 | 4280 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2014 | 2628 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 892 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2010 | 10748 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14766 | 0.020 |
Why?
|
Pyridines | 1 | 2018 | 2890 | 0.020 |
Why?
|
Regression Analysis | 1 | 2015 | 6331 | 0.020 |
Why?
|
Bone Density Conservation Agents | 1 | 2013 | 797 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2019 | 3618 | 0.020 |
Why?
|
Bone Marrow Examination | 1 | 2005 | 154 | 0.020 |
Why?
|
Treatment Failure | 1 | 2011 | 2658 | 0.020 |
Why?
|
Quinazolines | 1 | 2011 | 1369 | 0.020 |
Why?
|
Models, Biological | 1 | 2001 | 9464 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8504 | 0.020 |
Why?
|
Gene Expression | 1 | 2017 | 7587 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2020 | 18989 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2020 | 10455 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2011 | 2350 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2014 | 6507 | 0.010 |
Why?
|
Cell Survival | 1 | 2014 | 5750 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2015 | 8940 | 0.010 |
Why?
|
Software | 1 | 2017 | 4472 | 0.010 |
Why?
|
Piperidines | 1 | 2011 | 1667 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 1986 | 529 | 0.010 |
Why?
|
Protein Array Analysis | 1 | 2004 | 398 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 8068 | 0.010 |
Why?
|
Serologic Tests | 1 | 2004 | 382 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8736 | 0.010 |
Why?
|
Immunochemistry | 1 | 2001 | 116 | 0.010 |
Why?
|
Models, Statistical | 1 | 2015 | 5098 | 0.010 |
Why?
|
Estrogen Receptor beta | 1 | 2001 | 171 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2017 | 4881 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15925 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2017 | 22254 | 0.010 |
Why?
|
Colitis | 1 | 1988 | 1238 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18401 | 0.010 |
Why?
|
Seizures | 1 | 2012 | 2996 | 0.010 |
Why?
|
Dexamethasone | 1 | 2006 | 1963 | 0.010 |
Why?
|
Transcription Factors | 1 | 2018 | 12158 | 0.010 |
Why?
|
Reference Values | 2 | 2001 | 4918 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21526 | 0.010 |
Why?
|
Androstenedione | 1 | 1997 | 132 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18330 | 0.010 |
Why?
|
Estrogen Receptor alpha | 1 | 2001 | 581 | 0.010 |
Why?
|
beta-Galactosidase | 1 | 1997 | 573 | 0.010 |
Why?
|
Pain Measurement | 1 | 2006 | 3584 | 0.010 |
Why?
|
Luciferases | 1 | 1997 | 713 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 3804 | 0.010 |
Why?
|
Blotting, Western | 1 | 2001 | 5022 | 0.010 |
Why?
|
Infant | 1 | 2015 | 36485 | 0.010 |
Why?
|
Genes, Reporter | 1 | 1997 | 1526 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 1997 | 1743 | 0.010 |
Why?
|
Child, Preschool | 1 | 2015 | 42606 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2011 | 20169 | 0.010 |
Why?
|
Imidazoles | 1 | 1997 | 1169 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2017 | 21178 | 0.010 |
Why?
|
Transfection | 1 | 1997 | 5753 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 1997 | 3738 | 0.000 |
Why?
|
Aging | 1 | 1986 | 8729 | 0.000 |
Why?
|
Radioimmunoassay | 1 | 1986 | 861 | 0.000 |
Why?
|